168 related articles for article (PubMed ID: 28342234)
1. Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis.
Taniguchi T; Asano Y; Fukasawa T; Yoshizaki A; Sato S
J Dermatol; 2017 Aug; 44(8):967-971. PubMed ID: 28342234
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis.
Sakkas LI
Drug Des Devel Ther; 2016; 10():2723-8. PubMed ID: 27621593
[TBL] [Abstract][Full Text] [Related]
4. A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.
Taniguchi T; Miyagawa T; Tamaki Z; Nakamura K; Yamashita T; Saigusa R; Takahashi T; Toyama T; Ichimura Y; Yoshizaki A; Tada Y; Sugaya M; Kadono T; Sato S; Asano Y
Arch Dermatol Res; 2017 Dec; 309(10):833-842. PubMed ID: 29038846
[TBL] [Abstract][Full Text] [Related]
5. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.
Takahashi T; Asano Y; Noda S; Aozasa N; Akamata K; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2015 Sep; 173(3):681-9. PubMed ID: 25781362
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
Asano Y
Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
[TBL] [Abstract][Full Text] [Related]
7. Contribution to the peripheral vasculopathy and endothelial cell dysfunction by CXCL4 in Systemic Sclerosis.
Jiang Z; Chen C; Yang S; He H; Zhu X; Liang M
J Dermatol Sci; 2021 Oct; 104(1):63-73. PubMed ID: 34556381
[TBL] [Abstract][Full Text] [Related]
8. The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.
Mostmans Y; Cutolo M; Giddelo C; Decuman S; Melsens K; Declercq H; Vandecasteele E; De Keyser F; Distler O; Gutermuth J; Smith V
Autoimmun Rev; 2017 Aug; 16(8):774-786. PubMed ID: 28572048
[TBL] [Abstract][Full Text] [Related]
9. Plasma endothelial microparticles reflect the extent of capillaroscopic alterations and correlate with the severity of skin involvement in systemic sclerosis.
Michalska-Jakubus M; Kowal-Bielecka O; Smith V; Cutolo M; Krasowska D
Microvasc Res; 2017 Mar; 110():24-31. PubMed ID: 27889559
[TBL] [Abstract][Full Text] [Related]
10. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Shima Y; Kuwahara Y; Murota H; Kitaba S; Kawai M; Hirano T; Arimitsu J; Narazaki M; Hagihara K; Ogata A; Katayama I; Kawase I; Kishimoto T; Tanaka T
Rheumatology (Oxford); 2010 Dec; 49(12):2408-12. PubMed ID: 20819796
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature.
Zacay G; Levy Y
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):563-571. PubMed ID: 31174825
[TBL] [Abstract][Full Text] [Related]
12. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
Shima Y
Cells; 2021 May; 10(5):. PubMed ID: 34064515
[TBL] [Abstract][Full Text] [Related]
13. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab.
Shima Y; Hosen N; Hirano T; Arimitsu J; Nishida S; Hagihara K; Narazaki M; Ogata A; Tanaka T; Kishimoto T; Kumanogoh A
Mod Rheumatol; 2015 Jan; 25(1):134-7. PubMed ID: 24533556
[TBL] [Abstract][Full Text] [Related]
14. Nailfold capillaroscopic parameters and skin telangiectasia patterns in patients with systemic sclerosis.
Pizzorni C; Giampetruzzi AR; Mondino C; Facchiano A; Abeni D; Paolino S; Ruaro B; Smith V; Sulli A; Cutolo M
Microvasc Res; 2017 May; 111():20-24. PubMed ID: 27989404
[TBL] [Abstract][Full Text] [Related]
15. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma.
Shinriki S; Jono H; Ota K; Ueda M; Kudo M; Ota T; Oike Y; Endo M; Ibusuki M; Hiraki A; Nakayama H; Yoshitake Y; Shinohara M; Ando Y
Clin Cancer Res; 2009 Sep; 15(17):5426-34. PubMed ID: 19706815
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-10 attenuates tumour growth by inhibiting interleukin-6/signal transducer and activator of transcription 3 signalling in myeloid-derived suppressor cells.
Lee BR; Kwon BE; Hong EH; Shim A; Song JH; Kim HM; Chang SY; Kim YJ; Kweon MN; Youn JI; Ko HJ
Cancer Lett; 2016 Oct; 381(1):156-64. PubMed ID: 27431309
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
18. Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.
Saigusa R; Asano Y; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
Br J Dermatol; 2016 Feb; 174(2):338-47. PubMed ID: 26399195
[TBL] [Abstract][Full Text] [Related]
19. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
Shima Y
Mod Rheumatol; 2019 Mar; 29(2):294-301. PubMed ID: 30561237
[TBL] [Abstract][Full Text] [Related]
20. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
Asano Y
Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
